Monitoring and Treating Metabolic Abnormalities in Patients with Early Psychosis Initiated on Antipsychotic Medications. Community Ment Health J 2018 Aug;54(6):717-724
Date
11/12/2017Pubmed ID
29127566DOI
10.1007/s10597-017-0203-yScopus ID
2-s2.0-85033450253 (requires institutional sign-in at Scopus site) 8 CitationsAbstract
Antipsychotic medications carry an established lifetime risk of metabolic syndrome. This retrospective chart review evaluated feasibility of a metabolic monitoring clinical decision support tool (CDST) for weight, lipid, blood glucose, and blood pressure management of 163 clients in an early psychosis outpatient clinic over 2 years. Each parameter had at least 98 (60.1%) clients with a recorded value, the most being documented for weight with 112 (68.7%) clients. CDST adherence ranged from at least 54.3-100% for non-pharmacologic interventions (e.g. clinic counseling, referral to health program or primary care) and at least 33.3-100% for pharmacologic interventions (e.g. metformin). Though no baseline cardiometabolic abnormalities were identified, dyslipidemia and obesity were later found in 37 (22.7%) and 35 (21.5%) clients, respectively. Only 14 (8.6%) clients were prescribed medications for cardiometabolic abnormalities by psychiatrists in the clinic. Increasing focus on physical health is needed to better this population's long-term prognosis.
Author List
Bozymski KM, Whitten JA, Blair ME, Overley AM, Ott CAAuthor
Kevin M. Bozymski PharmD Assistant Professor in the School of Pharmacy Administration department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAdult
Antipsychotic Agents
Community Mental Health Centers
Decision Support Systems, Clinical
Dyslipidemias
Female
Health Behavior
Humans
Indiana
Male
Metabolic Syndrome
Middle Aged
Obesity
Psychotic Disorders
Retrospective Studies
Risk Factors
Schizophrenia
Schizophrenic Psychology
Young Adult
